Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This first-time-in-man study is mainly designed to assess the safety and tolerability of AADvac1 in the treatment of Alzheimer's disease.

AADvac1 is a vaccine directed against pathologically modified Alzheimer tau protein that is the main constituent of neurofibrillary tangles (NFTs), and is intended to be a disease-modifying treatment for Alzheimer's disease, i.e. to halt its progress.

As this study is a Phase I study focused on tolerability and safety, efficacy will be assessed in an exploratory manner.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease

NCT02031198

Alzheimer's Disease

COMPLETED PHASE1

24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease

NCT02579252

Alzheimer's Disease

COMPLETED PHASE2

Alzheimer's Tau Platform: Regimen A - AADvac1

NCT07167966

Preclinical Alzheimer's Disease Prodromal Alzheimer's Disease Alzheimer Disease

NOT_YET_RECRUITING PHASE2

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease

NCT04445831

Alzheimer's Disease Cognitive Impairment Tauopathies +4 more

COMPLETED PHASE1/PHASE2

A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia

NCT03174886

Primary Progressive Nonfluent Aphasia

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

AADvac1 is a candidate therapeutic vaccine for Alzheimer's disease that targets misfolded tau protein, a common denominator of neurofibrillary pathology. Based on preclinical results, the intervention is expected to reduce the number of neurofibrillary tangles, remove hyperphosphorylated tau protein and reduce the amount of oligomerized and insoluble pathological tau in the brain, to halt the spread of neurofibrillary pathology through the brain, and thus prevent associated cognitive decline.

The vaccine's antigenic determinant is a synthetic peptide derived from a tau protein sequence, which is coupled to keyhole limpet hemocyanin (KLH) and uses aluminum hydroxide (Alhydrogel) as an adjuvant.

At present AADvac1 is intended as an active immunotherapy for patients with diagnosed Alzheimer's disease (AD). Patients will receive 3 - 6 immunization doses; the raised titers of therapeutic antibodies and possible benefits of the treatment can extend beyond the duration of the study.

Because of the central role of pathological misfolded tau protein in the etiology of AD, the vaccine is expected to be more effective than active or passive immunotherapies aiming to eliminate the amyloid β plaques that have been clinically investigated so far.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo (adjuvant in saline solution)

Placebo patients will receive 1 dose of placebo per month over 3 months, for a total of 3 administrations.

Placebo consists of vaccine adjuvant in saline solution. Placebo is administered subcutaneously.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

The placebo contains the same buffer and adjuvant as AADvac1, but lacks the API.

AADvac1

AADvac1 patients will receive 1 dose of AADvac1 per month over 3 months, for a total of 3 administrations.

AADvac1 is a vaccine (single-use vials with solution ready for injection) AADvac1 is administered subcutaneously.

Group Type EXPERIMENTAL

AADvac1

Intervention Type BIOLOGICAL

AADvac1 is intended as an active vaccination for disease-modifying treatment of Alzheimer's disease.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AADvac1

AADvac1 is intended as an active vaccination for disease-modifying treatment of Alzheimer's disease.

Intervention Type BIOLOGICAL

Placebo

The placebo contains the same buffer and adjuvant as AADvac1, but lacks the API.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

(no commercial or INN name assigned yet) (no other names)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosis of probable Alzheimer's disease based on the NINCDS/ADRDA criteria.
2. MMSE 15-26.
3. stable dose of Alzheimer's Disease treatment since 3 months before screening visit or being untreated.
4. Hachinski Ischemia Scale ≤ 4.
5. MRI consistent with the diagnosis of AD.
6. Informed consent capability
7. Written informed consent signed and dated by the patient \& caregiver.
8. Age between 50 and 85 years.
9. Availability of partner/caregiver.
10. Adequate visual and auditory abilities and German language skills for neuropsychological testing.
11. Females either surgically sterile or 2+ years postmenopausal.
12. Participant on stable doses of all medications for concomitant illnesses according to medical history for at least 30 days prior to Visit 1 if considered relevant by the investigator.
13. Sexually active males must be using reliable contraception methods or be surgically sterile.

Exclusion Criteria

1. Pregnant women.
2. Participation in another clinical trial within 3 months before Visit 1.
3. Patients not expected to complete the clinical trial.
4. Presence or history of allergy to components of the vaccine, if considered relevant by the investigator.
5. Contraindication for MRI imaging (e.g. metallic endoprosthesis, stent implantation in the last 6 months).
6. Any of the following detected by brain MRI:

* Thromboembolic infarction
* Other focal lesions which may be responsible for the cognitive status of the patient
* More than one lacunar infarct with a diameter of less than 1.5 cm in any dimension
* Any lacunar infarct in a strategically important location such as the thalamus, hippocampus of either hemisphere, head of the left caudate
* White matter lesions involving more than 25% of the hemispheric white matter
7. Surgery (under general anaesthesia) within 3 months prior to study entry and scheduled surgery during the whole study period.
8. History and/or presence of autoimmune disease, if considered relevant by the investigator.
9. Recent (≤3 years since last specific treatment) history of cancer (Exceptions: basal cell carcinoma, intraepithelial cervical neoplasia).
10. Active infectious disease (e.g., Hepatitis B, C).
11. Presence and/or history of Immunodeficiency (e.g., HIV).
12. Significant systemic illness, if considered relevant by the investigator.
13. Hypothyroidism (patients with corrected hypothyroidism are eligible for the study if treatment has been stable for 3 months before study entry)
14. History of significant psychiatric illness such as schizophrenia, bipolar affective disorder or major depression.
15. Current depressive episode (Geriatric Depression Scale GDS \>5 at Visit 1).
16. Metabolic or toxic encephalopathy or dementia due to a general medical condition.
17. Alcoholism or substance abuse within the past year (alcohol or drug intoxication).
18. Wernicke's encephalopathy
19. History or evidence of any other CNS disorder that could be the cause of dementia (infectious or inflammatory/demyelinating CNS conditions, Creutzfeldt-Jakob disease, Parkinson's disease, Huntington's disease, brain tumour, subdural haematoma, etc.)
20. History or evidence of cerebrovascular disease (ischemic or haemorrhagic stroke, transient ischemic attack), or diagnosis of possible, probable or definite vascular dementia.
21. Epilepsy.
22. Prior and/or current treatment with experimental immunotherapeutics including IVIG or any vaccines for AD.
23. Current treatment with immunosuppressive drugs.
24. Change in dose of standard treatments for AD or hypothyroidism within 3 months prior to visit 1.
25. Change in dose of previous and current medications which the patient is taking because of consisting illnesses according medical history within the last 30 days prior to visit 1, if considered clinically relevant by the investigator.

Minimum Eligible Age

50 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No